Morning Overview on MSN
New prostate cancer immunotherapy cuts biomarkers by up to 99% in trial
A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...
A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.
A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.
Prostate cancer screening is essential for early detection, especially in high-risk groups like men over 50, African Americans, and those with a family history. Routine screening, including PSA tests ...
Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...
U.S. Senator John Boozman (R-AR) was recognized for his leadership in advancing policiies that prioritize enhanced care and research for prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results